Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours

Emerging Infectious Diseases

Volumn 16, Issue 10, 2010, Pages 1633-1636

  Inoue, Masafumi ^a   Barkham, Timothy ^b   Leo, Yee Sin ^c   Chan, Kwai Peng ^d   Chow, Angela ^b   Wong, Christopher W ^a   Lee, Raphael Tze Chuen ^a   Maurer Stroh, Sebastian ^a   Lin, Raymond ^e   Lin, Cui ^e  

^a AGENCY FOR SCIENCE   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c NATIONAL CENTRE FOR INFECTIOUS DISEASES   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e MINISTRY OF HEALTH   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

ADULT; ARTICLE; BODY TEMPERATURE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; COUGHING; EYE COLOR; FEMALE; FEVER; HUMAN; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MOLECULAR CLONING; MYALGIA; PANDEMIC INFLUENZA; PHYLOGENY; PYROSEQUENCING; SINGAPORE; SORE THROAT; VIRUS DETECTION; VIRUS ISOLATION; VIRUS STRAIN;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION; OSELTAMIVIR; PANDEMICS; PHYLOGENY; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 77958576283     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1610.100688     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention. Oseltamivir-resistant novel infl uenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:893-6.
2. Oseltamivir resistance in immunocompromised hospital patients. World Health Organization pandemic (H1N1) 2009 briefi ng note 18, 2009 Dec 2 [cited 2010 Apr 29]. http://www.who.int/csr/disease/swineflu/notes/briefing_20091202/en/index.html
3. Le QM, Wertheim HF, Duong TN, van Doorn HR, Tran Hien N, Horby P, the Vietnam H1N1 Investigation Team. A community cluster of oseltamivir-resistant cases of 2009 H1N1 infl uenza. N Engl J Med. 2010;362:86-7. DOI: 10.1056/NEJMc0910448
4. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis. 2010;50:1252-5. DOI: 10.1086/651605
5. Esposito S, Molteni CG, Colombo C, Daleno C, Daccò V, Lackenby A, et al. Oseltamivir-induced resistant pandemic A/H1N1 infl uenza virus in a child with cystic fi brosis and Pseudomonas aeruginosa infection. J Clin Virol. 2010;48:62-5. DOI: 10.1016/j. jcv.2010.02.019
6. Sy CL, Lee SSJ, Liu MT, Tsai HC, Chen YS. Rapid emergence of oseltamivir resistance. Emerg Infect Dis. 2010;16:723-5.
7. Moscana A. Global transmission of oseltamivir-resistant infl uenza. N Engl J Med. 2009; 360; 10:953-6.
8. Tramontana AR, George B, Hurt AC, Doyle JS, Langan K, Reid AB, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis. 2010;16:1068-75.
9. Poland GA, Jacobson RM, Ovsyannikova IG. Infl uenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis. 2009;48:1254-6. DOI: 10.1086/598989
10. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al.; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568-75. DOI: 10.1086/523584
11. Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically ill patients with 2009 infl uenza A (H1N1) in Mexico. JAMA. 2009;302:1880-7. DOI: 10.1001/ jama.2009.1536
12. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating infl uenza in healthy adults: systematic review and metaanalysis. BMJ. 2009;339:b5106. DOI: 10.1136/bmj.b5106